Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
When EC330 was compared to MCF-7 cells overexpressing LIF, EC330 demonstrated a considerable amount of apoptosis. It has also been demonstrated that EC330 inhibits and kills cancer-associated fibroblasts (CAFs) by blocking α-SMA but not β-tubulin [1].
|
---|---|
ln Vivo |
The EC330 therapy (0.1, 0.5, and 2.5 mg/kg) decreased the EC330 sulfide response in the MDA-MB-231 PDX model as well as the ovarian (IGROV-1) and triple-negative breast cancer (MDA-MB-231) cell xenograft models in a dose-dependent manner. The alcohol-cysteine residue is non-reactive and does not attach to ion channel off-targets, main receptors, or inhibitors. According to toxicity tests, EC330 is safe and well-tolerated, and it has wound bioavailability [1].
|
References |
[1]. Nair HB, et al. Discovery and preclinical pharmacology of EC330: A first-in-class leukemia inhibitory factor (LIF) inhibitor
|
Molecular Formula |
C30H32F2O2
|
---|---|
Molecular Weight |
462.570695877075
|
Exact Mass |
462.237
|
CAS # |
2016795-77-8
|
PubChem CID |
127020967
|
Appearance |
Typically exists as solid at room temperature
|
LogP |
4.7
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
4
|
Rotatable Bond Count |
3
|
Heavy Atom Count |
34
|
Complexity |
1000
|
Defined Atom Stereocenter Count |
5
|
SMILES |
C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C(C#C)(F)F)O)C5=CC=C(C=C5)C6CC6
|
InChi Key |
OWPPSPZDYGHPAN-GCNJZUOMSA-N
|
InChi Code |
InChI=1S/C30H32F2O2/c1-3-30(31,32)29(34)15-14-26-24-12-10-21-16-22(33)11-13-23(21)27(24)25(17-28(26,29)2)20-8-6-19(7-9-20)18-4-5-18/h1,6-9,16,18,24-26,34H,4-5,10-15,17H2,2H3/t24-,25+,26-,28-,29-/m0/s1
|
Chemical Name |
(8S,11R,13S,14S,17S)-11-(4-cyclopropylphenyl)-17-(1,1-difluoroprop-2-ynyl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~20 mg/mL (~43.24 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (4.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1618 mL | 10.8092 mL | 21.6183 mL | |
5 mM | 0.4324 mL | 2.1618 mL | 4.3237 mL | |
10 mM | 0.2162 mL | 1.0809 mL | 2.1618 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.